CN1260715A - Treatment of diabetes with rosiglitazone and insulin - Google Patents
Treatment of diabetes with rosiglitazone and insulin Download PDFInfo
- Publication number
- CN1260715A CN1260715A CN98806223A CN98806223A CN1260715A CN 1260715 A CN1260715 A CN 1260715A CN 98806223 A CN98806223 A CN 98806223A CN 98806223 A CN98806223 A CN 98806223A CN 1260715 A CN1260715 A CN 1260715A
- Authority
- CN
- China
- Prior art keywords
- chemical compound
- diabetes
- insulin
- gives
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of Compound (I) and insulin to a mammal in need thereof.
Description
The present invention relates to a kind of Therapeutic Method, particularly treat diabetes, especially noninsulindependent diabetes (NIDDM) or type ii diabetes and with the method for diabetes diseases associated.
Insulin is the first line therapeutic agent of type i diabetes (or insulin-dependent diabetes).It also is used as antihyperglycemic agents in the treatment of NIDDM.
European patent application discloses the 0th, 306, relates to certain thiazolidine diketone derivative No. 228, discloses it and has hyperglycemia and short serum lipids reduces active.Disclosed a kind of specific thiazole alkane diketone is 5-[4-[2-(N-methyl-N-(2-pyridine radicals) amino) ethyoxyl among the EP 0306228] benzyl] thiazolidine-2,4-diketone (hereinafter being called " chemical compound (I) ").WO94/05659 discloses some salt of chemical compound (I), comprises the maleate of embodiment 1.
International patent application discloses the method that the thiazolidine diketone derivative that discloses for WO97/05875 number by giving NIDDM patient effective dose and/or related compound reduce its exogenous insulin dosage.
Now, have wonderful demonstration to show, the combination of the chemical compound of specified quantitative (I) and insulin can provide useful especially glycemic control effect, and therefore this compositions is particularly useful for treating diabetes, especially type ii diabetes and with the diabetes diseases associated.
Therefore, the invention provides a kind of mammal such as people's treatment of diabetes method, especially type ii diabetes and with the Therapeutic Method of diabetes diseases associated, this method comprises the chemical compound (I) and the insulin of nontoxic, the effective and pharmaceutically acceptable amount of the mammal that needs this treatment.
Preferably, the dosage of chemical compound (I) is no more than 12mg, especially when the every day administration.
The administration simultaneously of this method inclusion compound (I) and insulin or the two order administration.
Administration simultaneously comprises and gives a kind of preparation that comprises insulin sensitizer such as chemical compound (I) and insulin, perhaps more suitably, comprises the administration simultaneously basically of the independent preparation of every kind of activating agent.
A particular aspects, this method comprises and gives 2-12mg chemical compound (I), especially when the every day administration.
Particularly, this method comprises and gives 2-4,4-8 or 8-12mg chemical compound (I) every day.
Particularly, this method comprises and gives 2-4mg chemical compound (I), especially when the every day administration.
Particularly, this method comprise give 4-8mg, such as greater than 4 as 4.1 to the chemical compounds (I) of 8mg, especially when the every day administration.
Particularly, this method comprises and gives 8-12mg chemical compound (I), especially when the every day administration.
Preferably, this method comprises and gives 2mg chemical compound (I), especially when the every day administration.
Preferably, this method comprises and gives 4mg chemical compound (I), especially when the every day administration.
Preferably, this method comprises and gives 8mg chemical compound (I), especially when the every day administration.
Should be appreciated that chemical compound (I) and insulin with each self administration of medication of pharmaceutically acceptable form, comprise for chemical compound (I), its pharmaceutically acceptable derivates such as pharmaceutically acceptable salt and solvate.
The suitable pharmaceutically acceptable salt form of chemical compound (I) comprises those that put down in writing among EP 0306228 and the WO94/05659.The salt of preferred pharmaceutical compositions is maleate.
The suitable pharmaceutically acceptable solvation form of chemical compound (I) comprises those that put down in writing among EP 0306228 and the WO94/05659, particularly hydrate.
Suitable pharmaceutically acceptable insulin form is meant to be mentioned in canonical reference book such as Britain and American Pharmacopeia, Remington ' s pharmaceutical science (Remington ' s PharmaceuticalSciences) (Mack publishing company) and Extra Pharmacopoeia Martindale (London, The Pharmaceutical publishing house) (for example referring to the 31st edition the 341st page and wherein referer).
Chemical compound (I), or its pharmaceutically acceptable salt, or its pharmaceutically acceptable solvate can utilize the known method preparation, for example those disclosed among EP 0306228 and the WO94/05659.The open text of EP 0306228 and WO94/05659 is incorporated herein by reference.
Chemical compound (I) can be with a kind of existence the in the multiple tautomeric form, and all tautomerism types all are included in the term chemical compound (I), can be independent tautomerism type or its mixture.Chemical compound (I) contains chiral carbon atom, therefore can exist with one or more stereoisomeric forms in any ratio, and term chemical compound (I) comprises all these isomeric forms, no matter is independent isomer, or mixture of isomers, comprises racemic modification.
Insulin prepares according to known method, these methods are at the canonical reference book, such as Britain and American Pharmacopeia, Remington ' s pharmaceutical science (Remington ' s PharmaceuticalScience) (Mack publishing company) and Extra Pharmacopoeia Martindale (London, The Pharmaceutical publishing house) finds in (for example referring to the 31st edition the 341st page and wherein referer), or in these handbook, mention.
Term used herein " with the diabetes diseases associated " comprise with diabetes self diseases associated and with the diabetes complications associated with arterial system.
" with diabetes self diseases associated " comprises hyperglycemia, and insulin resistance comprises insulin resistance and the obesity day after tomorrow.Other and diabetes self diseases associated comprise hypertension and cardiovascular disease, especially atherosclerosis and with the insulin resistance diseases associated.Comprise polycystic ovary syndrome and inductive insulin resistance of steroid and gestational diabetes with the insulin resistance diseases associated.
" with the diabetes complications associated with arterial system " comprises kidney disease, especially relevant with type ii diabetes kidney disease, neuropathy and retinopathy.
The kidney disease relevant with type ii diabetes comprises nephropathy, glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis and late period kidney disease.
Term used herein " pharmaceutically acceptable " comprises people and veterinary purpose: for example term " pharmaceutically acceptable " comprises veterinarily acceptable chemical compound.
For fear of query, when the scalar that provides formula (I) chemical compound of pharmaceutically acceptable form herein, when comprising the mg amount, this scalar itself provides about chemical compound (I): for example the formula of 2mg maleate form (I) chemical compound is meant, contains the amount of the maleate of 2mg chemical compound (I).
Diabetes are preferably type ii diabetes.
The useful especially glycemic control effect that provides by treatment of the present invention is designated as with respect to the synergism that contrasts, and this contrast is contemplated to the effect summation of independent active agents.
Glycemic control can utilize conventional method to describe its feature, for example by measuring glycemic control index commonly used, such as fasting plasma glucose or glycosylated hemoglobin (Hb Alc).These indexes can utilize standard method to determine, for example at Tuescher A, Richterich, P., Schweiz.med.Wschr.101 (1971), in 345 and 390 and Frank P., " measuring the monitoring diabetics ", those that describe in the clinical prods (Clinical Products) 1988 with glycosylated hemoglobin.
One preferred aspect, when treatment and when using according to the present invention, the dosage level of used various activating agents will less than reach add merely and the glycemic control effect dosage that may need.
In the methods of the invention, active medicine is preferably with the form administration of pharmaceutical composition.As implied above, this compositions can comprise above-mentioned two kinds of medicines or only a kind of medicine.
In treatment of the present invention, insulin is generally with injection or other known method administrations, those that put down in writing in the handbook of for example mentioning in this article.Therefore following comment about compositions, preparation and suitable medication refers to compositions, preparation and the administration of chemical compound (I).
Usually said composition is suitable for oral administration.But they also are fit to other administering mode, for example parenteral, sublingual administration or percutaneous dosing.
Said composition can be tablet, capsule, powder, granule, lozenge, suppository, can reconstruct powder or such as liquid preparation forms such as oral or aseptic parenteral solution or suspensions.
In order to reach the concordance of administration, the present composition is preferably single agent form.
The single agent representation that is used for oral administration can be tablet and capsule, and can contain conventional excipients such as binding agent, for example syrup, arabic gum, gelatin, sorbitol, tragacanth or polyvinylpyrrolidone; Filler, for example lactose, sugar, corn starch, calcium phosphate, sorbitol or glycine; Tabletting lubricant, for example magnesium stearate; Disintegrating agent, for example starch, polyvinylpyrrolidone, Explotab or microcrystalline Cellulose; Or pharmaceutically acceptable wetting agent, such as sodium lauryl sulphate.
Solid oral composition can prepare with conventional mixing, filling or pressed disc method.Repeating married operation can be used for activating agent fully is distributed to the compositions of using a large amount of filleies.Conventional in such operation yes this area.Well-known method coating during tablet can prepare according to conventional medicine, particularly enteric coated.
Oral liquid can be the form of example emulsion, syrup or elixir, perhaps can be used as dry products and exists, and water or other suitable carriers reconstitute again before the use.This liquid preparation can contain conventional additives, such as suspending agent, and for example sorbitol, syrup, methylcellulose, gelatin, hydroxyethyl-cellulose, carboxymethyl cellulose, aluminium stearate gel, hydrogenation edible fat; Emulsifying agent, for example lecithin, anhydro sorbitol monooleate or arabic gum; Anhydrous carrier (can comprise edible oil), for example almond oil, heating up in a steamer Oleum Cocois, oily ester such as glyceride, propylene glycol or ethanol; Antiseptic, for example methyl parahydroxybenzoate or propyl ester or sorbic acid; If desired, also can add conventional flavoring agent or coloring agent.
For parenteral, can utilize this chemical compound and sterile carrier to prepare the liquid unit dosage forms, and, can suspend or be dissolved in the carrier according to used concentration.When preparation solution, can be filled in bottle or the ampoule afterwards and sealing with this compound dissolution in water for injection and filtration sterilization.Advantageously, adjuvant such as local anesthetic, antiseptic and buffer agent can be dissolved in this carrier.For enhanced stability, recharge in the bottle after can be with said composition freezing, and under vacuum, remove moisture.The parenteral suspension is to prepare with identical in fact mode, and just chemical compound (I) is not to be dissolved in the carrier, but is suspended in the carrier, and sterilization is not accomplished by filtration.This chemical compound can be sterilized in sterile carrier by contact the back resuspending with oxirane.Advantageously, in said composition, comprise surfactant or wetting agent to promote the uniform distribution of this chemical compound.
According to different medications, compositions can contain the active substance of 0.1% to 99% weight, preferred 10-60% weight.
If desired, compositions can be to follow the packaged form of the operation instruction of written or printing.
These compositionss are prepared according to conventional method, such as herein with the canonical reference book in those disclosed method, for example disclosed in Britain and American Pharmacopeia, Remington ' s pharmaceutical science (Remington ' sPharmaceutical Sciences) (Mack publishing company) and Extra Pharmacopoeia Martindale (London, The Pharmaceutical publishing house) (for example referring to the 31st edition the 341st page and wherein referer) and Harry ' s cosmetic conduct and learning (Leonard Hill Books).
These compositionss are preferably to make unit dosage forms with the amount that relevant daily dose suits.
Proper dosage comprises that the unit dose of formula (I) chemical compound comprises 1,2,3,4,5,6,7,8,9,10,11 or 12mg chemical compound (I).
In treatment, these two kinds of medicines can the administration every day 1-6 time, but most preferably administration every day 1 or 2 times.
Suitable insulin dose, comprise unit dose, comprise those that describe or mention in handbook such as Britain and American Pharmacopeia, Remington ' s pharmaceutical science (Remington ' s Pharmaceutical Science) (Mack publishing company) and the Extra Pharmacopoeia Martindale (London, The Pharmaceutical publishing house) (for example referring to the 31st edition the 341st page and wherein referer).
Scope 2-4mg comprises 2.1-4,2.2-4,2.3-4,2.4-4,2.5-4,2.6-4,2.7-4,2.8-4,2.9-4 or 3-4mg.
Scope 4-8mg comprises 4.1-8,4.2-8,4.3-8,4.4-8,4.5-8,4.6-8,4.7-8,4.8-8,4.9-8,5-8,6-8 or 7-8mg.
Scope 8-12mg comprises 8.1-12,8.2-12,8.3-12,8.4-12,8.5-12,8.6-12,8.7-12,8.8-12,8.9-12,9-12,10-12 or 11-12mg.
Compositions of the present invention or method have confirmed there is not disadvantageous toxicology effect in above-mentioned dosage range.
Following examples have further been set forth the present invention and have not been played any restriction.
Chemical compound (I) compositions
The A concentrate formulation
The sieve that about 2/3rds lactose monohydrates are suitable excessively also mixes with the maleate of levigate chemical compound (I).The sieve that Explotab, hydroxypropyl emthylcellulose, microcrystalline Cellulose and remaining lactose is suitable excessively also joins in this mixture, continues then to mix.The gained mixture is with the wet granulation of purifying waste water.Then this wet granular is sieved, dry on fluidized bed dryer, dried granule further sieves, and finally makes it even.
The component % of granule concentrate becomes levigate chemical compound (I) 13.25 (pure maleate) Explotab 5.00 hydroxypropyl methylcellulose 2910 5.00 microcrystalline Cellulose 20.00 lactose monohydrates of component (%) maleate form, and conventional level adds to 100 * that purify waste water
* remove in the course of processing.
B is mixed with tablet with concentrate
The granule that makes is above placed the tipping bucket type blender.About 2/3rds lactose are sieved and add this blender.Microcrystalline Cellulose, starch ethanol sodium, magnesium stearate and residue lactose are sieved and add this blender, this mixture is blended together.Gained mixture rotary tablet machine tabletting then, 1,2 and the 4mg tablet respectively suppress 150mg, 300mg is pressed into the 8mg tablet.
Then these tablet cores are transferred in the tablet coating device, with hot-air (about 65 ℃) preheating and carry out film coating, increased 2.0%-3.5% up to tablet weight.
Amount (mg/ sheet) tablet strength 1.0mg 2.0mg 4.0mg 8.0mg active component: compound (I) maleate concentrate particle 10.00 20.00 40.00 80.00 other compositions: Explotab 6.96 6.46 5.46 10.92 microcrystalline celluloses 27.85 25.85 21.85 43.70 lactose monohydrates 104.44 96.94 81.94 163.88 dolomols 0.75 0.75 0.75 1.50 tablet cores gross weight 150.0 150.0 150.0 300.0 contains moisture film coating substance 4.5 4.5 4.5 9.0 film coating tablet gross weights 154.5 154.5 154.5 309.0
Claims (15)
1. treat mammiferous diabetes and with the method for diabetes diseases associated, this method comprises the chemical compound (I) and the insulin of effective, the nontoxic and pharmaceutically acceptable amount of the mammal that needs this treatment.
2. the method for claim 1, it comprises the chemical compound (I) that is no more than 12mg.
3. method as claimed in claim 1 or 2, it comprises and gives 2-12mg chemical compound (I).
4. as each described method of claim 1-3, it comprises and gives 2-4,4-8 or 8-12mg chemical compound (I).
5. as each described method of claim 1-3, it comprises and gives 2-4mg chemical compound (I).
6. as each described method of claim 1-3, it comprises and gives 4-8mg chemical compound (I).
7. as each described method of claim 1-3, it comprises and gives 8-12mg chemical compound (I).
8. as each described method of claim 1-3, it comprises and gives 2mg chemical compound (I).
9. as each described method of claim 1-3, it comprises and gives 4mg chemical compound (I).
10. as each described method of claim 1-3, it comprises and gives 8mg chemical compound (I).
11. pharmaceutical composition, its inclusion compound (I), insulin and pharmaceutically acceptable carrier.
12. compositions as claimed in claim 11, wherein insulin sensitizer is chemical compound (I).
13. as claim 11 or 12 described compositionss, it comprises the chemical compound (I) that is no more than 12mg or 2-12mg.
14. as the pharmaceutical composition of active treatment material, wherein said composition inclusion compound (I), insulin and pharmaceutically acceptable carrier.
15. be used for the treatment of diabetes and with the pharmaceutical composition of diabetes diseases associated, wherein said composition inclusion compound (I), insulin and pharmaceutically acceptable carrier.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9712866.4 | 1997-06-18 | ||
| GBGB9712866.4A GB9712866D0 (en) | 1997-06-18 | 1997-06-18 | Novel method of treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1260715A true CN1260715A (en) | 2000-07-19 |
| CN1133431C CN1133431C (en) | 2004-01-07 |
Family
ID=10814527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB988062232A Expired - Fee Related CN1133431C (en) | 1997-06-18 | 1998-06-15 | Treatment of diabetes with rosiglitazone and insulin |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP0999837A1 (en) |
| JP (1) | JP2002504138A (en) |
| KR (1) | KR20010013843A (en) |
| CN (1) | CN1133431C (en) |
| AP (1) | AP1287A (en) |
| AR (2) | AR012997A1 (en) |
| AU (1) | AU8216398A (en) |
| BG (1) | BG104059A (en) |
| BR (1) | BR9810444A (en) |
| CA (1) | CA2294141A1 (en) |
| CO (1) | CO4940454A1 (en) |
| DZ (1) | DZ2521A1 (en) |
| EA (1) | EA004800B1 (en) |
| GB (1) | GB9712866D0 (en) |
| HU (1) | HUP0003260A3 (en) |
| ID (1) | ID23951A (en) |
| IL (1) | IL133143A0 (en) |
| IN (1) | IN189723B (en) |
| MA (1) | MA26511A1 (en) |
| NO (1) | NO996265D0 (en) |
| OA (1) | OA11517A (en) |
| PE (1) | PE104499A1 (en) |
| PL (1) | PL343123A1 (en) |
| SK (1) | SK179399A3 (en) |
| TR (1) | TR199903095T2 (en) |
| TW (1) | TW587937B (en) |
| UA (1) | UA70299C2 (en) |
| UY (1) | UY25050A1 (en) |
| WO (1) | WO1998057636A1 (en) |
| ZA (1) | ZA985237B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102389427A (en) * | 2011-10-10 | 2012-03-28 | 成都恒瑞制药有限公司 | Solid oral preparation containing rosiglitazone and cetirizine hydrochloride |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291495B1 (en) * | 1997-02-24 | 2001-09-18 | Robert B. Rieveley | Method and composition for the treatment of diabetes |
| TWI249401B (en) | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
| MXPA01010820A (en) | 1999-04-23 | 2002-06-04 | Smithkline Beecham Plc | Novel pharmaceutical. |
| DE60036367T2 (en) * | 1999-06-21 | 2008-05-29 | Eli Lilly And Co., Indianapolis | SYNERGISTIC USE OF THIAZOLIDINEDIONES AND GLUCAGON-LIKE PEPTIDE-1 AND THEIR AGONISTS FOR THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES |
| JP2003503356A (en) * | 1999-06-25 | 2003-01-28 | メドトロニック ミニメド インコーポレイテッド | Multidrug diabetes treatment |
| US6468507B1 (en) * | 2000-05-01 | 2002-10-22 | Aeropharm Technology, Inc. | Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer |
| GB0023970D0 (en) * | 2000-09-29 | 2000-11-15 | Smithkline Beecham Plc | Novel pharmaceutical |
| US6852694B2 (en) | 2001-02-21 | 2005-02-08 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
| US6531461B1 (en) | 2001-06-04 | 2003-03-11 | Louis Obyo Obyo Nelson | Medicament for the treatment of diabetes |
| US20020198203A1 (en) * | 2001-06-07 | 2002-12-26 | Wyeth | Combination of a PTPase inhibitor and a thiazolidinedione agent |
| US6737401B2 (en) | 2001-06-28 | 2004-05-18 | Metronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
| ES2295692T3 (en) * | 2002-11-08 | 2008-04-16 | F. Hoffmann-La Roche Ag | NEW DERIVATIVES OF 4-ALCOXIOXAZOL REPLACED AS PPAR AGONISTS. |
| US7264813B2 (en) | 2003-09-24 | 2007-09-04 | Nikken Sohonsha Corporation | Therapeutic uses of Dunaliella powder |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1714652A3 (en) * | 1993-09-15 | 2007-01-17 | Sankyo Company, Limited | Use of thiazolidinediones to prevent or delay onset of niddm |
| KR19990036290A (en) * | 1995-08-10 | 1999-05-25 | 로즈 암스트롱 | Reduction of Exogenous Insulin Dosage in Non-insulin-Dependent Diabetic Patients |
| ATE259227T1 (en) * | 1995-09-18 | 2004-02-15 | Ligand Pharm Inc | TREATMENT OF NIDDM (NON-INSULIN DEPENDENT DIABETES MELLITUS) WITH RXR AGONISTS |
-
1997
- 1997-06-18 GB GBGB9712866.4A patent/GB9712866D0/en active Pending
-
1998
- 1998-06-15 IL IL13314398A patent/IL133143A0/en unknown
- 1998-06-15 ID IDW991627A patent/ID23951A/en unknown
- 1998-06-15 WO PCT/EP1998/003692 patent/WO1998057636A1/en not_active Application Discontinuation
- 1998-06-15 HU HU0003260A patent/HUP0003260A3/en unknown
- 1998-06-15 SK SK1793-99A patent/SK179399A3/en unknown
- 1998-06-15 TR TR1999/03095T patent/TR199903095T2/en unknown
- 1998-06-15 CA CA002294141A patent/CA2294141A1/en not_active Abandoned
- 1998-06-15 UA UA99126881A patent/UA70299C2/en unknown
- 1998-06-15 JP JP50375799A patent/JP2002504138A/en not_active Ceased
- 1998-06-15 EP EP98932169A patent/EP0999837A1/en not_active Withdrawn
- 1998-06-15 KR KR1019997011864A patent/KR20010013843A/en not_active Application Discontinuation
- 1998-06-15 AP APAP/P/1999/001718A patent/AP1287A/en active
- 1998-06-15 CN CNB988062232A patent/CN1133431C/en not_active Expired - Fee Related
- 1998-06-15 EA EA200000042A patent/EA004800B1/en not_active IP Right Cessation
- 1998-06-15 PL PL98343123A patent/PL343123A1/en unknown
- 1998-06-15 AU AU82163/98A patent/AU8216398A/en not_active Abandoned
- 1998-06-15 BR BR9810444-6A patent/BR9810444A/en not_active IP Right Cessation
- 1998-06-17 TW TW087109619A patent/TW587937B/en not_active IP Right Cessation
- 1998-06-17 DZ DZ980131A patent/DZ2521A1/en active
- 1998-06-17 AR ARP980102883A patent/AR012997A1/en not_active Application Discontinuation
- 1998-06-17 MA MA25122A patent/MA26511A1/en unknown
- 1998-06-17 AR ARP980102886A patent/AR015894A1/en not_active Application Discontinuation
- 1998-06-17 ZA ZA9805237A patent/ZA985237B/en unknown
- 1998-06-18 IN IN1698DE1998 patent/IN189723B/en unknown
- 1998-06-18 UY UY25050A patent/UY25050A1/en unknown
- 1998-06-18 CO CO98034654A patent/CO4940454A1/en unknown
- 1998-06-18 PE PE1998000535A patent/PE104499A1/en not_active Application Discontinuation
-
1999
- 1999-12-17 OA OA9900296A patent/OA11517A/en unknown
- 1999-12-17 NO NO996265A patent/NO996265D0/en not_active Application Discontinuation
-
2000
- 2000-01-06 BG BG104059A patent/BG104059A/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102389427A (en) * | 2011-10-10 | 2012-03-28 | 成都恒瑞制药有限公司 | Solid oral preparation containing rosiglitazone and cetirizine hydrochloride |
Also Published As
| Publication number | Publication date |
|---|---|
| GB9712866D0 (en) | 1997-08-20 |
| PL343123A1 (en) | 2001-07-30 |
| AR015894A1 (en) | 2001-05-30 |
| ID23951A (en) | 2000-06-08 |
| CO4940454A1 (en) | 2000-07-24 |
| EA004800B1 (en) | 2004-08-26 |
| AP1287A (en) | 2004-06-26 |
| IN189723B (en) | 2003-04-19 |
| TW587937B (en) | 2004-05-21 |
| SK179399A3 (en) | 2000-11-07 |
| EA200000042A1 (en) | 2000-08-28 |
| AR012997A1 (en) | 2000-11-22 |
| DZ2521A1 (en) | 2003-02-08 |
| HUP0003260A3 (en) | 2001-12-28 |
| KR20010013843A (en) | 2001-02-26 |
| NO996265L (en) | 1999-12-17 |
| CA2294141A1 (en) | 1998-12-23 |
| HUP0003260A2 (en) | 2001-05-28 |
| EP0999837A1 (en) | 2000-05-17 |
| JP2002504138A (en) | 2002-02-05 |
| IL133143A0 (en) | 2001-03-19 |
| AP9901718A0 (en) | 1999-12-31 |
| OA11517A (en) | 2004-02-04 |
| TR199903095T2 (en) | 2000-08-21 |
| BR9810444A (en) | 2000-09-05 |
| BG104059A (en) | 2000-10-31 |
| AU8216398A (en) | 1999-01-04 |
| MA26511A1 (en) | 2004-12-20 |
| PE104499A1 (en) | 2000-01-13 |
| UY25050A1 (en) | 2000-09-29 |
| NO996265D0 (en) | 1999-12-17 |
| ZA985237B (en) | 2000-02-17 |
| WO1998057636A1 (en) | 1998-12-23 |
| CN1133431C (en) | 2004-01-07 |
| UA70299C2 (en) | 2004-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1114404C (en) | Treatment of diabetes with thiazolidinedione and metformin | |
| CN1133431C (en) | Treatment of diabetes with rosiglitazone and insulin | |
| CN1443068A (en) | Combinations of depepotidyl peptidase IV inhibitors and other antidiabetic agents for treatment of diabete mellitus | |
| CN1264303A (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide | |
| CN1112926C (en) | Composition containing 5- [ 4- [ 2- (N-methyl-N-2-pyridyl) amino) ethoxy ] benzyl ] thiazolidine-2, 4-dione | |
| CN1263467A (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor | |
| CN1168451C (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
| CN1274282A (en) | Treatment of diabetes with thiazolidinedione and Alpha-glucosidase inhibitor | |
| CN1264302A (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
| CN100431540C (en) | Treatment of diabetes with thiazolidinedione and metformin | |
| CN1281358A (en) | Use of thiazolidinediones for treatment of hyperglycaemia | |
| CN1281359A (en) | Use of thiazolidinediones for treatment of hyperglycaemia | |
| CN1310619A (en) | Use of glucose uptake enhancer for reducing post-ischemic injury of the heart | |
| NZ515554A (en) | Treatment of diabetes with thiazolidinedione and metformin | |
| NZ518076A (en) | 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (BRL49653) for treating non-insulin dependent diabetes (NIDDM) | |
| HU226960B1 (en) | Combination of a dioxothiazolidine and metformin, and pharmaceutical compositions containing the same for the treatment of diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |